Andrew R. Robbins - 19 May 2026 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Reporting relationship: President and CEO, Director
Issuer ticker: COGT
Reported as of: 19 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 May 2026, 16:30:06 UTC
Prior SEC filing: 19 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Evan D. Kearns, Attorney-in-Fact

Key filing fact

Andrew R. Robbins filed Form 4 for Cogent Biosciences, Inc. (COGT) on 21 May 2026.

Key facts

This page summarizes Andrew R. Robbins's Form 4 filing for Cogent Biosciences, Inc. (COGT).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 21 May 2026, 16:30.

Change

Previous filing in this sequence was filed on 19 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001590157 Primary reporting owner

Robbins Andrew R

Relationship: President and CEO, Director
Address: C/O COGENT BIOSCIENCES, INC., 180 THIRD AVENUE, 4TH FLOOR, WALTHAM
Signature: /s/ Evan D. Kearns, Attorney-in-Fact
Signature date: 21 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COGT transaction

Common Stock

Gift

Transaction value
Shares: -160,000
Change %: -24%
Price: $0.000000^*
Shares after: 497,503
Date: 19 May 2026
Ownership: Direct
Footnotes: F1

COGT transaction

Common Stock

Gift

Transaction value
Shares: +160,000
Change %
Price: $0.000000^*
Shares after: 160,000
Date: 19 May 2026
Ownership: By trust
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .